| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
A Methodology for Successfully Producing Global Translations of Patient Reported Outcome Measures for Use in Multiple Countries
|
Two, Rebecca
|
|
2010
|
13 |
1 |
p. 128-131
4 p.
|
artikel
|
| 2 |
A Multinational Study of Health State Preference Values Associated with Chronic Myelogenous Leukemia
|
Szabo, Shelagh M.
|
|
2010
|
13 |
1 |
p. 103-111
9 p.
|
artikel
|
| 3 |
Beyond AWP … Way Beyond
|
Willke, Richard J.
|
|
2010
|
13 |
1 |
p. 1-
1 p.
|
artikel
|
| 4 |
Budget Impact Analysis of Thrombolysis for Stroke in Spain: A Discrete Event Simulation Model
|
Mar, Javier
|
|
2010
|
13 |
1 |
p. 69-76
8 p.
|
artikel
|
| 5 |
Calibration of Disease Simulation Model Using an Engineering Approach
|
Vanni, Tazio
|
|
2010
|
13 |
1 |
p. 157-
1 p.
|
artikel
|
| 6 |
Cost–Benefit Analysis of Preventing Nosocomial Bloodstream Infections among Hemodialysis Patients in Canada in 2004
|
Hong, Zhiyong
|
|
2010
|
13 |
1 |
p. 42-45
4 p.
|
artikel
|
| 7 |
Cost-Effectiveness of Sorafenib for Second-Line Treatment of Advanced Renal Cell Carcinoma
|
Hoyle, Martin
|
|
2010
|
13 |
1 |
p. 55-60
6 p.
|
artikel
|
| 8 |
Cost-Effectiveness of Temsirolimus for First Line Treatment of Advanced Renal Cell Carcinoma
|
Hoyle, Martin
|
|
2010
|
13 |
1 |
p. 61-68
8 p.
|
artikel
|
| 9 |
Erratum
|
|
|
2010
|
13 |
1 |
p. 158-
1 p.
|
artikel
|
| 10 |
Good Research Practices for Measuring Drug Costs in Cost-Effectiveness Analyses: A Managed Care Perspective: The ISPOR Drug Cost Task Force Report—Part III
|
Mansley, Edward C.
|
|
2010
|
13 |
1 |
p. 14-17
4 p.
|
artikel
|
| 11 |
Good Research Practices for Measuring Drug Costs in Cost Effectiveness Analyses: An Industry Perspective: The ISPOR Drug Cost Task Force Report—Part V
|
Mycka, Jack M.
|
|
2010
|
13 |
1 |
p. 25-27
3 p.
|
artikel
|
| 12 |
Good Research Practices for Measuring Drug Costs in Cost-Effectiveness Analyses: An International Perspective: The ISPOR Drug Cost Task Force Report—Part VI
|
Shi, Lizheng
|
|
2010
|
13 |
1 |
p. 28-33
6 p.
|
artikel
|
| 13 |
Good Research Practices for Measuring Drug Costs in Cost-Effectiveness Analyses: A Societal Perspective: The ISPOR Drug Cost Task Force Report—Part II
|
Garrison Jr., Louis P.
|
|
2010
|
13 |
1 |
p. 8-13
6 p.
|
artikel
|
| 14 |
Good Research Practices for Measuring Drug Costs in Cost Effectiveness Analyses: Issues and Recommendations: The ISPOR Drug Cost Task Force Report—Part I
|
Hay, Joel W.
|
|
2010
|
13 |
1 |
p. 3-7
5 p.
|
artikel
|
| 15 |
Good Research Practices for Measuring Drug Costs in Cost-Effectiveness Analyses: Medicare, Medicaid and Other US Government Payers Perspectives: The ISPOR Drug Cost Task Force Report—Part IV
|
Mullins, C. Daniel
|
|
2010
|
13 |
1 |
p. 18-24
7 p.
|
artikel
|
| 16 |
Instrumental Variables in Influenza Vaccination Studies: Mission Impossible?!
|
Groenwold, Rolf H.H.
|
|
2010
|
13 |
1 |
p. 132-137
6 p.
|
artikel
|
| 17 |
ISPOR Code of Ethics
|
|
|
2010
|
13 |
1 |
p. viii-
1 p.
|
artikel
|
| 18 |
Patient Characteristics Impacting Health State Index Scores, Measured by the EQ-5D of Females with Stress Urinary Incontinence Symptoms
|
Tincello, Douglas
|
|
2010
|
13 |
1 |
p. 112-118
7 p.
|
artikel
|
| 19 |
Prevalence of Respiratory Syncytial Virus (RSV) Risk Factors and Cost Implications of Immunoprophylaxis to Infants 32 to 35 Weeks Gestation for Health Plans in the United States
|
Krilov, Leonard R.
|
|
2010
|
13 |
1 |
p. 77-86
10 p.
|
artikel
|
| 20 |
Psychometric Development of the Individualized Retinopathy-Dependent Quality of Life Questionnaire (RetDQoL)
|
Brose, Leonie S.
|
|
2010
|
13 |
1 |
p. 119-127
9 p.
|
artikel
|
| 21 |
Relationship between Adherence Level to Statins, Clinical Issues and Health-Care Costs in Real-Life Clinical Setting
|
Dragomir, Alice
|
|
2010
|
13 |
1 |
p. 87-94
8 p.
|
artikel
|
| 22 |
Relationship between Health-Related Quality of Life, Pain, and Functional Disability in Neuropathic Pain Patients with Failed Back Surgery Syndrome
|
Manca, Andrea
|
|
2010
|
13 |
1 |
p. 95-102
8 p.
|
artikel
|
| 23 |
Relationships among Self-Management, Patient Perceptions of Care, and Health Economic Outcomes for Decision-Making and Clinical Practice in Type 2 Diabetes
|
Cobden, David S.
|
|
2010
|
13 |
1 |
p. 138-147
10 p.
|
artikel
|
| 24 |
The Impact of Fewer Hip Fractures with Risedronate Versus Alendronate in the First Year of Treatment: Modeled German Cost-Effectiveness Analysis
|
Thompson, Melissa
|
|
2010
|
13 |
1 |
p. 46-54
9 p.
|
artikel
|
| 25 |
The Impact of Pharmaceutical Cost Containment Policies on the Range of Medicines Available and Subsidized in Finland and New Zealand
|
Aaltonen, Katri
|
|
2010
|
13 |
1 |
p. 148-156
9 p.
|
artikel
|
| 26 |
The Multinational Nature of Cost-Effectiveness Analyses Alongside Multinational Clinical Trials
|
Rivero-Arias, Oliver
|
|
2010
|
13 |
1 |
p. 34-41
8 p.
|
artikel
|
| 27 |
What's in a Perspective?
|
Glick, Henry A.
|
|
2010
|
13 |
1 |
p. 2-
1 p.
|
artikel
|
Tijdschrift beschrijving